9 completed, 3 active not recruiting, 3 recruiting, 1 terminated. 10 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Active not recruiting 3, Completed 3, Recruiting 3, Terminated 1 |
| Phase 1 | 9 | Completed 8, Withdrawn 1 |
Follow Etrumadenant: new trials by email Literature Review of Etrumadenant trials Research Report on Etrumadenant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer Quemliclustat, Etrumadenant, Zimberelimab - Oligometastatic Prostate Cancer | Phase 2 | Recruiting | Catherine Spina | 23 | 2023-07-01 | 2025-05-20 |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Pemetrexed, Zimberelimab, Etrumadenant - Urothelial Carcinoma, Metastatic Cancer | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2023-06-13 | 2026-08-14 |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Etrumadenant, Zimberelimab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2023-05-23 | 2026-10-22 |
| A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants Etrumadenant - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 24 | 2022-02-10 | 2024-05-24 |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer SRF617, etrumadenant, zimberelimab - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 2 | Terminated | Coherus Oncology, Inc. | 16 | 2022-01-17 | 2025-05-08 |
| A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants Etrumadenant, Itraconazole - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 20 | 2021-10-20 | 2024-05-24 |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer Zimberelimab, Domvanalimab, Etrumadenant - Non Small Cell Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Active not recruiting | Washington University School of Medicine | 30 | 2021-08-04 | 2026-06-08 |
| An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. AB680, Etrumadenant, Zimberelimab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 227 | 2021-05-10 | 2025-10-20 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Etrumadenant, Zimberelimab, Quemliclustat - Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 173 | 2020-07-07 | 2025-07-22 |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Domvanalimab, Etrumadenant, Zimberelimab - Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer | Phase 2 | Completed | Arcus Biosciences, Inc. | 151 | 2020-05-28 | 2026-06-15 |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy Atezolizumab, Tocilizumab, Etrumadenant - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Recruiting | David Oh | 68 | 2019-10-30 | 2026-06-04 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Etrumadenant, Zimberelimab, Carboplatin - Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 77 | 2019-04-01 | 2024-12-09 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies etrumadenant, mFOLFOX - GastroEsophageal Cancer, Colorectal Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 44 | 2018-11-18 | 2024-05-24 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD) - TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 35 | 2018-10-15 | 2024-05-24 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Etrumadenant, Zimberelimab - Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | Arcus Biosciences, Inc. | 48 | 2018-07-24 | 2024-05-24 |
Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Breast Neoplasms (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Liposarcoma (1) · Lung Neoplasms (1)
Arcus Biosciences, Inc. (9) · Catherine Spina (1) · Coherus Oncology, Inc. (1) · David Oh (1) · Gulam Manji (1) · Jennifer Choe (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Washington University School of Medicine (1)
United States (16) · Australia (4) · Canada (3) · South Korea (3) · Singapore (2) · Taiwan (2) · France (1) · Hong Kong (1) · Italy (1) · Spain (1) · United Kingdom (1)
Catherine S. Spina, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · David Oh, MD, PhD (1) · Gulam Manji, MD, PhD (1) · Jennifer Choe, MD, PhD (1) · Omar Alhalabi, MD (1) · Sandra D'Angelo, MD (1) · Vienna Reichert, PhD (1)